Genscript Probio Congratulates Xlifesciences On The Start Of Taest16001 Early Phase Clinical Trial

Genscript Probio Congratulates Xlifesciences On The Start Of Taest16001 Early Phase Clinical Trial

By, Admin 28 March 2020

Nanjing, China, March 27, 2020 /Prnewswire/ -- Genscript Usa Inc. Xlifesciences, A Partner Of Genscript Probio (Genscript'S Cdmo Segment) Announced That The Early Phase Clinical Trial Of Taest16001 Project Has Been Started. Genscript Probio Extends Congratulations On This.This Clinical Trial Project Is China'S First Tcr-T Project Targeted At Solid Tumor Therapy, Marking A Milestone In Immunotherapy In China. In 2019, Xlifesciences Entrusted Tcr-T Products With Complete Independent Intellectual Property Rights To Genscript Probio. It Is The First Cooperation Project Between The Parties, Where Genscript Probio Works On Plasmid And Virus Process Development And Clinical Manufacturing And Will Be Further Responsible For Commercial Manufacturing."We Congratulate Xlifesciences On The Successful Launch Of Taest16001 Early Phase Clinical Trial, Which Marks A Milestone In The Industry," Said Dr. Brian Min, Ceo Of Genscript Probio. "We Are Honored To Offer Technology And Manufacturing Support In Such A Meaningful Project. With A One-Stop High-Quality Plasmid And Virus Platform, Genscript Probio Facilitates Xlifesciences To Complete All Pre-Clinical Cmc Research For Ind Filing. We Will Continue To Follow Up On The Clinical Trial. We Wish That The Clinical Project Proceeds Smoothly So As To Relieve Patients From Pain As Soon As Possible. We Are Optimistic About The Prospects Of The Project. As China'S First Company That Has Built The Plasmid Facility For Gene And Cell Therapy, Genscript Probio Has Well-Established Technological Platform And Quality System, And Is Capable Of Providing Quality Services To More Customers.About Xiangxue Life SciencesXiangxue Life Sciences (Xlifesc) Is A Biopharmaceutical Company Focused On Tcr-Based Therapies For Cancer. Our Main Proprietary Technological Platforms Are Composed Of: (1) High Affinity T Cell Activation Core (Hatac); (2) Tcr Affinity Enhancing Specific T Cell Therapy (Taest). The Two Platforms Have Been Fully Developed To The Clinic-Ready Stage. As A Result, An Independently-Owned Intellectual Property Portfolio Has Been Constructed Which Spans Across The Whole Spectrum Of Tcr-Related Technologies Including The Identification Of Tumor-Specific Antigens, Antigen-Specific Tcrs, And The Optimization Of Antigen-Specific Tcrs In Terms Of Affinity And Stability, Etc. To Date, Many Domestic And Pct Applications Have Been Filed.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!